Escient Pharmaceuticals, Inc.
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects with Atopic Dermatitis
Volunteers needed for up to a 14 week long clinical trial with up to 5 office visits for an investigational product. $1,250.00 stipend available. Additional compensation will be available for participants travelling further than 62.1 miles (100 Km).
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18+ years of age (max age = 80)
2.) Have MILD to MODERATE eczema (atopic dermatitis)
3.) Minimum of 3% eczema affected body surface area (max 20%) to be determined by Investigator at Screening Visit.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Allergic to lidocaine
2.) Unwilling to discontinue current atopic dermatitis treatments
3.) Female who is pregnant or breastfeeding
ClinicalTrials.gov Identifier: NCT https://clinicaltrials.gov/study/NCT06144424?cond=Atopic%20Dermatitis&term=escient&rank=1
Escient Pharmaceuticals, Inc Logo
We love our patients, so feel free to visit during normal business hours.
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2024 Principle Research Solutions,llc - All Rights Reserved.
Your One-Stop Research SOLUTION
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.